Gene Therapy Costs: What Plan Sponsors Should Know

Gene therapies are both medically transformative and financially complex. These advanced treatments involve introducing or altering genetic material to treat disease, offering life-changing outcomes for patients with limited options. Since their introduction in 2017, more than 30 therapies have received FDA approval, with many more expected in the coming years. 

While the clinical benefits are significant, the financial implications are substantial. Individual treatments for conditions like muscular dystrophy and hemophilia can exceed $3 million, with some therapies surpassing $4 million per treatment. Even though these treatments are often administered only once, the cost can create immediate and significant financial exposure for health plan sponsors. 

As more therapies enter the market, employers must take a proactive approach to understanding how these costs impact their health plans and what strategies are available to manage risk. 

Why Gene Therapy Costs Create Financial Risk for Employers 

For employers, the challenge is not just the cost itself, but the unpredictability of when and how these treatments will impact the plan. 

Self-funded plans offer greater flexibility in funding strategy and plan design, along with increased transparency into healthcare spending. However, that flexibility also comes with full financial responsibility. A single gene therapy claim can significantly disrupt expected plan performance and create unplanned budget pressure. 

Because many gene therapies are used to treat dependent children, decisions around coverage can also carry employee experience and reputational considerations. Employers are not just managing cost, they are balancing financial responsibility with employee trust and wellbeing. 

Strategies to Manage Gene Therapy Risk and Cost Exposure 

Employers have several options to manage the financial risk associated with gene therapies. Each approach comes with tradeoffs between cost control, risk exposure, and employee impact. 

Self-Funded Plan Exclusion 

Self-funded plans can exclude coverage for gene therapies, eliminating the need to fund these high-cost treatments. While this approach removes financial exposure, it may create employee relations challenges, particularly when treatments impact dependents. 

Gene Therapy Carve-Out Policies 

Carve-out policies shift financial responsibility to a third party, allowing employers to avoid direct exposure to gene therapy costs. 

• These policies can provide significant financial protection  
• Coverage may vary depending on the carrier and policy structure  
• Newer policies may offer broader coverage but at a higher cost  

While carve-outs can reduce risk, they must be carefully evaluated to ensure they provide meaningful protection relative to their cost. 

Stop Loss Insurance 

For many employers, stop loss protection is the most effective way to manage catastrophic risk while maintaining flexibility in plan design. 

Stop loss insurance allows employers to manage claims risk and large claimant exposure by transferring financial liability above a defined threshold. 

Carrier approaches to gene therapy risk vary. Some apply conservative pricing through pooling charges, while others report lower-than-expected utilization and take a more moderate approach. 

Key considerations include: 

• Whether gene therapy risk is built into base pricing  
• How carriers handle high-risk individuals (laser provisions)  
• Whether plan design is mirrored to ensure coverage alignment  
• Availability of rate caps and no-new-laser provisions at renewal  

The OneDigital Stop Loss Center of Excellence works with carrier partners to negotiate more favorable terms, including protection against new lasers and alignment between plan design and stop loss coverage. 

The Bottom Line: A Strategic Approach to High-Cost Claims 

Gene therapies are not a one-off challenge. They represent a broader shift in how high-cost treatments are entering the healthcare system. 

Employers must move beyond reactive decision-making and take a more structured approach to evaluating risk, cost, and coverage strategy. 

The right solution will depend on the organization’s risk tolerance, financial position, and long-term benefits strategy. Whether through exclusions, carve-outs, or stop loss protection, the goal is not simply to avoid cost, but to manage it in a way that aligns with both financial and workforce priorities. 

Protect Your Plan from High-Cost Claims with a Smarter Strategy 

Gene therapy costs are only one example of how healthcare risk is evolving. Employers need a strategy that provides both protection and flexibility. 

The OneDigital Stop Loss Center of Excellence helps employers: 

• Evaluate claims risk and large claimant exposure  
• Structure stop loss programs aligned to plan design  
• Navigate carrier strategies and underwriting approaches  
• Protect against emerging high-cost therapies like gene treatments  

Talk with a OneDigital Stop Loss Expert to assess your current risk strategy and build a plan that protects your organization from high-cost claims.